Zeria To Develop Eisai PPI In Japan
This article was originally published in PharmAsia News
Executive Summary
In another sign of a continued shift into new areas such as oncology, Eisai has shed most Japanese rights to its pipeline proton pump inhibitor (PPI) E3710 by way of a licensing deal with mid-sized firm Zeria.